Daclizumab, a humanized monoclonal antibody, has carved a niche in pharmaceutical research primarily due to its specific interaction with the CD25 antigen, a subunit of the high-affinity interleukin-2 (IL-2) receptor. While its clinical applications in organ transplantation and multiple sclerosis (MS) treatment have been discontinued, its utility as a research tool remains significant. For B2B buyers and researchers, understanding Daclizumab’s profile from a chemical supplier’s perspective is essential.

The primary mechanism of Daclizumab involves reversibly binding to CD25, thereby inhibiting IL-2 binding and subsequently modulating T-cell activation. This precise targeting made it effective in preventing the immune system from rejecting transplanted organs and was explored as a treatment for relapsing forms of MS. The ability to specifically influence T-cell responses makes Daclizumab a valuable compound for studies investigating immune dysregulation. Many chemical manufacturers and suppliers, especially those based in China, offer Daclizumab for research purposes, catering to a global scientific demand.

The decision to withdraw Daclizumab from the market was driven by serious safety concerns, notably the occurrence of inflammatory brain disorders and potential liver damage. These risks necessitated a re-evaluation of its benefit-risk profile for clinical use. This historical context is vital for researchers who continue to purchase Daclizumab. It informs experimental design, emphasizes the need for careful handling, and provides data for developing safer immunomodulatory agents. When a research scientist or procurement manager decides to buy Daclizumab, understanding these safety implications is part of responsible procurement.

Beyond its direct applications, Daclizumab serves as a critical reagent for fundamental research in immunology. Its well-defined target allows scientists to probe complex immune pathways, study T-cell subset dynamics, and investigate the role of the IL-2 signaling pathway in various disease models. The availability of high-purity Daclizumab from specialized suppliers ensures that researchers have access to reliable materials for their experiments, whether it's for in vitro assays, cell culture studies, or in vivo models. The sourcing of such specialized antibodies is a routine aspect of R&D operations.

For procurement professionals, identifying dependable sources for Daclizumab is key. This involves evaluating suppliers based on product specifications, lot consistency, pricing, and customer support. Reputable manufacturers provide comprehensive documentation to support their products. The global supply chain for such specialized biochemicals means that researchers can often find competitive pricing and efficient delivery from international manufacturers. Therefore, exploring options from established chemical suppliers is a standard practice for many research institutions.

In summary, Daclizumab represents a significant chapter in immunomodulatory therapy. Although its clinical journey concluded due to safety concerns, its scientific value persists. Researchers focused on immunology and autoimmune diseases will continue to find Daclizumab a useful tool for their investigations. Sourcing this antibody requires careful consideration of supplier reliability and product quality, ensuring that scientific endeavors are supported by the best available resources.